FMP
NLS Pharmaceutics AG
NLSP
NASDAQ
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
0.137 USD
0.0043 (3.15%)
About
ceo
Mr. Alexander Zwyer M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://nlspharma.com
exchange
NASDAQ
Description
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
CIK
0001783036
ISIN
CH0523961370
CUSIP
H57830103
Address
The Circle 6
Phone
41 44 512 21 50
Country
CH
Employee
6
IPO Date
Jan 29, 2021
Summary
CIK
0001783036
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
H57830103
ISIN
CH0523961370
Country
CH
Price
0.14
Beta
-0.84
Volume Avg.
589.78k
Market Cap
5.41M
Shares
-
52-Week
0.113-1.53
DCF
0.45
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.27
P/B
-
Website
https://nlspharma.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest NLSP News
It looks like there's no news available.
